MIT Jameel Clinic

What MIT Jameel Clinic does

MIT Jameel Clinic is a research center within the Massachusetts Institute of Technology, founded in 2018 as a joint initiative between Community Jameel and MIT and operating under MIT's Schwarzman College of Computing. Its mission is translational research at the intersection of artificial intelligence and health, spanning clinical AI for disease detection and AI-driven drug discovery. The clinic develops and deploys proprietary AI tools including SYBIL (lung cancer risk assessment from low-dose CT scans, predicting risk up to six years in advance) and MIRAI (breast cancer risk assessment from mammograms, predicting risk up to five years in advance), alongside research tools such as DiffDock, Chemprop, CardioComposer, and the MEDS data-standardization framework. Its work spans predictive analytics, computer vision, NLP, generative AI, audio-based diagnostics, and multimodal modeling.

The clinic serves three primary constituencies: (1) hospitals and healthcare systems globally, which receive free access to cutting-edge clinical AI tools and MIT researcher expertise through a network of 110 hospitals across 31 countries and 5 continents, supported by a Wellcome Trust grant; (2) academic and research institutions, through open research output and conferences such as MoML and AI CURES; and (3) healthcare professionals and industry leaders, through online and in-person educational programs delivered in collaboration with MIT Sloan School of Management. Regional leads in India, Latin America, and MENASA drive adoption and partnership development.

Commercially, the clinic is structured as a non-commercial research unit. Its revenue mechanics are indirect: philanthropy (Community Jameel founding support), grants (Wellcome Trust), co-development partnerships with pharmaceutical companies (Janssen Research & Development, Takeda), and enrollment fees from educational programs. Clinical AI tools are provided free of charge to partner hospitals, and the research output is disseminated through academic publications, conference presentations, and educational programs rather than software licensing. AI modalities span text, image, audio, structured data, and multimodal inputs, with the work led by world-renowned faculty including Regina Barzilay and James Collins.

Name

MIT Jameel Clinic

Legal name

MIT Jameel Clinic

Website

https://jclinic.mit.edu

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

1–10 employees

Short description

MIT Jameel Clinic is an MIT research center founded in 2018 that develops and deploys proprietary clinical AI tools — including SYBIL and MIRAI for cancer risk assessment — to a global network of 110 hospitals across 31 countries, supported by Wellcome Trust and Community Jameel.

Ownership category

akta.pro rank

Product category

Clinical AI Research and Tools

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Health Services (8000)

akta.pro primary industry

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

Keywords

• Clinical AI tools
• Drug discovery AI
• Cancer risk assessment
• Medical imaging AI
• Healthcare AI research

Headquarters

HQ city

Cambridge

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure

Revenue model

1. Research Funding and Grants: Supported by grants, foundations, and donors including Wellcome Trust partnership for hospital network operations and tool deployment.
2. Educational Programs: Revenue from online short courses and in-person programs offered in collaboration with MIT Sloan School of Management.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels10 records

Core offering

MIT Jameel Clinic is a research center that develops, validates, and deploys clinical AI tools (including SYBIL for lung cancer risk assessment and MIRAI for breast cancer risk assessment) and AI-driven drug discovery tools (DiffDock, Chemprop) through a global network of 110 hospitals across 31 countries. It provides these AI tools free of charge to partner hospitals and supplements its research mission with educational programs offered through MIT Sloan School of Management.

Product overview

MIT Jameel Clinic is a research institute at MIT (founded 2018) pioneering translational research in clinical AI and AI-driven drug discovery. The clinic operates as a research center rather than a commercial product company, offering a portfolio of AI tools including SYBIL (lung cancer risk assessment) and MIRAI (breast cancer risk assessment) deployed through a global hospital network of 110 hospitals in 31 countries. Research tools include DiffDock for molecular binding prediction, Chemprop for antibiotic discovery, and CardioComposer for anatomical model generation. The clinic also runs educational programs (online courses and in-person training on AI in healthcare), annual conferences (AI CURES, MoML), and supports postdoctoral fellowships. Its AI capabilities span predictive analytics, computer vision, NLP, generative AI, and process automation for applications in early disease detection, drug discovery, and healthcare optimization.

Differentiator

Problem solved

Functional benefit

Products and services

• SYBIL SYBIL is a lung cancer risk assessment tool that uses a noninvasive deep learning system to assess lung cancer risk in low-dose CT scans up to 6 years in advance. It is deployed through the global hospital network for partner hospitals to enable earlier detection of lung cancer risk in clinical practice.
• MIRAI MIRAI is a breast cancer risk assessment tool using a noninvasive deep learning system to assess breast cancer risk in mammograms up to 5 years in advance. Deployed globally through partner hospitals with over 6,000 women screened since 2022, enabling risk-based screening programs.
• DiffDock DiffDock is an AI tool that uses deep learning to predict how small molecules bind to proteins, identifying possible protein targets and potential mechanisms of action for drug candidates including antibiotics and other therapeutics.
• Chemprop Chemprop is a neural network-based model that correlates molecular features (bond types, atomic number, electronic charge) with properties such as solubility and microbial growth inhibition, used for antibiotic discovery and molecular property prediction.
• CardioComposer CardioComposer is a programmable framework leveraging differentiable geometry for compositional control of anatomical diffusion models. It generates multi-class anatomical label maps from interpretable ellipsoidal primitives, enabling compositional control over cardiac and vascular structures for medical device evaluation.
• Hospital Network The Hospital Network is a global service of 110 hospitals across 31 countries that provides free access to cutting-edge AI tools and MIT Jameel Clinic researchers' expertise, supported by Wellcome Trust funding. Regional leads in India, Latin America, and MENASA facilitate implementation.
• Artificial Intelligence in Health Care (Online Course) A 6-week online short course offered by MIT Sloan School of Management and MIT Jameel Clinic covering AI applications and limitations in healthcare. Led by Regina Barzilay, the course targets clinicians, medical professionals, and industry leaders seeking to understand and implement AI in healthcare.
• Artificial Intelligence in Pharma and Biotech (Online Course) A 6-week online short course on how machine learning drives new drug discovery, biological modeling, and clinical trial management in the pharmaceutical industry, offered through MIT Sloan School of Management.
• Transforming Healthcare with AI (In-Person Program) A 2-day intensive in-person program covering foundational AI knowledge, practical applications in patient care, diagnostics, hospital management, and ethical considerations for healthcare professionals and industry leaders.

Quantifiable outcome

• SYBIL can detect lung cancer risk up to 6 years in advance from low-dose CT scans
• +2 more outcomes

Named customers5 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability11 records

Feature6 records

Partnerships

Three partnerships are on record, tiered major and core.

• Janssen Research & DevelopmentmajorStrategic or Co-development PartnerData science focused collaboration to advance AI solutions to optimize medical research and innovation. Part of Johnson & Johnson.
• TakedamajorStrategic or Co-development PartnerMIT-Takeda Program creating educational opportunities and supporting cutting-edge research to positively impact human health. Part of MIT School of Engineering partnership.
• MIT Schwarzman College of ComputingcoreStrategic or Co-development PartnerCo-founding partner of MIT Jameel Clinic. The clinic is an initiative of MIT Schwarzman College of Computing alongside Community Jameel.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• BenevolentAI: AI drug discovery company applying knowledge graphs and ML to identify novel drug targets. Comparable on AI-driven drug discovery and partnerships with pharma, though with a stronger commercial drug pipeline orientation.
• Nanox (formerly Zebra Medical Vision): AI imaging company (absorbing Zebra Medical Vision's tech) developing deep learning algorithms for radiology reading. Comparable on AI imaging for cancer detection in hospital deployments.
• Arterys: Cloud-native medical imaging AI platform with FDA-cleared deep learning tools for radiology workflows. Comparable on AI medical imaging for cancer and radiology, and an example of a commercial path Jameel tools could take.

Direct peers

• PathAI: AI-powered pathology platform used by hospitals and pharma for diagnostic and drug discovery applications. Closely comparable on AI-enabled diagnostics and AI-driven drug discovery collaboration model with pharmaceutical partners.
• Recursion Pharmaceuticals: AI-driven drug discovery company combining high-throughput biology with machine learning for therapeutics development. Comparable on AI-driven drug discovery emphasis, particularly around DiffDock/Chemprop-style molecular ML tooling.
• Owkin: AI biotech that partners with hospitals and pharma to deploy federated learning models on patient data for diagnostics and drug discovery. Closely comparable on the hospital-network-plus-pharma-partnership model and clinical AI focus.
• Paige.AI: Digital pathology AI company deploying deep learning on histopathology images for cancer diagnosis. Comparable on AI image-based cancer detection tooling and hospital deployment model, though Paige focuses narrowly on pathology.
• Tempus Labs: AI-driven precision medicine company applying machine learning to clinical and molecular data for diagnostics and treatment selection. Directly comparable to MIT Jameel Clinic on clinical AI for disease detection and patient outcome prediction in hospital settings.
• Insitro: Machine learning-driven drug discovery platform combining induced pluripotent stem cell biology with ML models. Comparable on the AI-enabled biologic discovery platform model with pharma partnerships.

Broad incumbents

• Google Health (Alphabet): Broader Google initiative applying AI to medical imaging, EHR data, and consumer health. Comparable on AI medical imaging (including mammography research) and NLP on clinical text, with vastly larger resources but less hospital-partnership focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/AIHealthMIT
• YouTubeyoutube.com/c/MITJameelClinicAIHealth
• LinkedInlinkedin.com/company/aihealthmit
• Instagraminstagram.com/aihealthmit

Revenue estimate

Valuation estimate

Number of profiles

Profiles7 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MIT Jameel Clinic